Related Experiment Video
Updated: Jan 24, 2026

Imaging Dpp Release from a Drosophila Wing Disc
Published on: October 30, 2019
DPP-4 INHIBITORS INCREASE THE INCIDENCE OF ARTHRITIS/ARTHRALGIA BUT DO NOT AFFECT AUTOIMMUNITY
Z A Sayiner1, B Okyar2, B Kısacık3
1Gaziantep University School of Medicine, Dept. of Endocrinology and Metabolism, Gaziantep, Turkey.
Aims:
In August 2015, FDA published a black box declaring that DPP-4 inhibitors may cause severe joint pains. The impact on autoimmunity marker positivity of these drugs has not been comprehensively evaluated. We compared the incidence of arthritis/arthralgia in patients with T2DM who were using DPP-4 inhibitors and patients who were not using.
Methods:
A number of 93 DPP-4 inhibitor users and 107 non-users were included into the study. Arthritis/arthralgia were found in 41 of 93 (44.1%) DPP-4 inhibitor users and in 19 of 107 (17.8%) non-users (p<0.05).
Results:
No inflammatory rheumatological condition was identified in 27 of 41 (65.9%) patients in DPP-4 inhibitor user group as well as in 13 of 19 (68.4%) patients in non-user group (p>0.05). After adjusting for gender the incidence for arthritis/arthralgia was significantly increased in the DPP-4 inhibitor user group (p value for any DPP-inhibitor <0.05). There was 3.77 times increased risk for arthritis/arthralgia in the DPP-4 inhibitor using group (p value= 0.001) and this risk increases 2.43 times for each year of DPP-4 inhibitor usage.
Conclusions:
Arthritis/arthralgia were more common among T2DM patients who were using DPP-4 inhibitors compared to non-users, but the seropositivity did not differ between DPP-4 inhibitor users and non-users.
Insights
DPP-4 inhibitors, used for type 2 diabetes, are linked to increased joint pain incidence. This study found a higher risk of arthritis/arthralgia in users, but no difference in autoimmune markers.
Area of Science:
- Endocrinology
- Rheumatology
- Pharmacology
Background:
- FDA issued a black box warning in 2015 regarding DPP-4 inhibitors and severe joint pain.
- The effect of DPP-4 inhibitors on autoimmunity markers in patients with type 2 diabetes (T2DM) requires further investigation.
Purpose of the Study:
- To compare the incidence of arthritis/arthralgia in T2DM patients using DPP-4 inhibitors versus non-users.
- To evaluate the impact of DPP-4 inhibitors on autoimmunity marker positivity.
Main Methods:
- Retrospective study comparing 93 DPP-4 inhibitor users and 107 non-users with T2DM.
- Incidence of arthritis/arthralgia and seropositivity for rheumatological conditions were assessed.
Main Results:
- Arthritis/arthralgia occurred in 44.1% of DPP-4 inhibitor users vs. 17.8% of non-users (p<0.05).
- No significant difference in inflammatory rheumatological conditions or seropositivity was observed between groups.
- Adjusted analysis revealed a significantly increased incidence of arthritis/arthralgia in DPP-4 inhibitor users (p<0.05).
- The risk of arthritis/arthralgia was 3.77 times higher in DPP-4 inhibitor users (p=0.001), increasing by 2.43 times per year of use.
Conclusions:
- Arthritis/arthralgia are more common in T2DM patients using DPP-4 inhibitors compared to non-users.
- DPP-4 inhibitor use did not significantly affect seropositivity for autoimmune markers.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Role of Affect in Interpersonal Attraction
The Influence of Affect on Cognition
The Influence of Cognition on Affect
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...

